157 related articles for article (PubMed ID: 10866139)
1. Absorption, first-pass metabolism, and disposition of itraconazole in rats.
Yoo SD; Kang E; Jun H; Shin BS; Lee KC; Lee KH
Chem Pharm Bull (Tokyo); 2000 Jun; 48(6):798-801. PubMed ID: 10866139
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of itraconazole in diabetic rats.
Lee U; Choi YH; Kim SH; Lee BK
Antimicrob Agents Chemother; 2010 Feb; 54(2):931-3. PubMed ID: 19995926
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats.
Quinney SK; Galinsky RE; Jiyamapa-Serna VA; Chen Y; Hamman MA; Hall SD; Kimura RE
Drug Metab Dispos; 2008 Jun; 36(6):1097-101. PubMed ID: 18339815
[TBL] [Abstract][Full Text] [Related]
4. Interspecies comparison of the oral absorption of itraconazole in laboratory animals.
Yoo SD; Kang E; Shin BS; Jun H; Lee SH; Lee KC; Lee KH
Arch Pharm Res; 2002 Jun; 25(3):387-91. PubMed ID: 12135115
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients.
Hennig S; Wainwright CE; Bell SC; Miller H; Friberg LE; Charles BG
Clin Pharmacokinet; 2006; 45(11):1099-114. PubMed ID: 17048974
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect.
Shin JH; Choi KY; Kim YC; Lee MG
Antimicrob Agents Chemother; 2004 May; 48(5):1756-62. PubMed ID: 15105131
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, blood partition, and tissue distribution of itraconazole.
Lee JH; Shin JH; Lee MG
Res Commun Mol Pathol Pharmacol; 2004; 115-116():203-15. PubMed ID: 17564318
[TBL] [Abstract][Full Text] [Related]
8. Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles.
Yoo SD; Lee SH; Kang E; Jun H; Jung JY; Park JW; Lee KH
Drug Dev Ind Pharm; 2000 Jan; 26(1):27-34. PubMed ID: 10677807
[TBL] [Abstract][Full Text] [Related]
9. Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole.
DiNunzio JC; Miller DA; Yang W; McGinity JW; Williams RO
Mol Pharm; 2008; 5(6):968-80. PubMed ID: 19434851
[TBL] [Abstract][Full Text] [Related]
10. Effects of cysteine on the pharmacokinetics of itraconazole in rats with protein-calorie malnutrition.
Lee AK; Ahn CY; Kim EJ; Kwon JW; Kim SG; Chung SJ; Shim CK; Lee MG
Biopharm Drug Dispos; 2003 Mar; 24(2):63-70. PubMed ID: 12619051
[TBL] [Abstract][Full Text] [Related]
11. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin.
Ducharme MP; Slaughter RL; Warbasse LH; Chandrasekar PH; Van de Velde V; Mannens G; Edwards DJ
Clin Pharmacol Ther; 1995 Dec; 58(6):617-24. PubMed ID: 8529326
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic interaction between itraconazole and metformin in rats: competitive inhibition of metabolism of each drug by each other via hepatic and intestinal CYP3A1/2.
Choi YH; Lee U; Lee BK; Lee MG
Br J Pharmacol; 2010 Oct; 161(4):815-29. PubMed ID: 20860661
[TBL] [Abstract][Full Text] [Related]
13. Increased oral bioavailability of itraconazole and its active metabolite, 7-hydroxyitraconazole, when coadministered with a vitamin C beverage in healthy participants.
Bae SK; Park SJ; Shim EJ; Mun JH; Kim EY; Shin JG; Shon JH
J Clin Pharmacol; 2011 Mar; 51(3):444-51. PubMed ID: 20400647
[No Abstract] [Full Text] [Related]
14. A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption.
Hong JY; Kim JK; Song YK; Park JS; Kim CK
J Control Release; 2006 Jan; 110(2):332-338. PubMed ID: 16297483
[TBL] [Abstract][Full Text] [Related]
15. Liquid chromatographic method for the determination of plasma itraconazole and its hydroxy metabolite in pharmacokinetic/bioavailability studies.
Wong JW; Nisar UR; Yuen KH
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Dec; 798(2):355-60. PubMed ID: 14643517
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention.
Duret C; Merlos R; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Eur J Pharm Biopharm; 2014 Jan; 86(1):46-54. PubMed ID: 23523546
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis.
Reynes J; Bazin C; Ajana F; Datry A; Le Moing JP; Chwetzoff E; Levron JC
Antimicrob Agents Chemother; 1997 Nov; 41(11):2554-8. PubMed ID: 9371367
[TBL] [Abstract][Full Text] [Related]
18. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect.
Varis T; Kivistö KT; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Nov; 68(5):487-94. PubMed ID: 11103751
[TBL] [Abstract][Full Text] [Related]
19. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children.
de Repentigny L; Ratelle J; Leclerc JM; Cornu G; Sokal EM; Jacqmin P; De Beule K
Antimicrob Agents Chemother; 1998 Feb; 42(2):404-8. PubMed ID: 9527794
[TBL] [Abstract][Full Text] [Related]
20. Examining sex-related differences in enteric itraconazole metabolism in healthy adults using grapefruit juice.
Gubbins PO; Gurley BJ; Williams DK; Penzak SR; McConnell SA; Franks AM; Saccente M
Eur J Clin Pharmacol; 2008 Mar; 64(3):293-301. PubMed ID: 18172627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
